ArticleCell reports. Medicine2020
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19.
Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 3 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Comprehensive proteomics and meta-analysis of COVID-19 host response.Nature communications · 2023Pooled it
- Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies.International journal of epidemiology · 2022Pooled it
- A composite ranking of risk factors for COVID-19 time-to-event data from a Turkish cohort.Computational biology and chemistry · 2022Pooled it
- The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.The Journal of clinical investigation · 2021Trial
- Hierarchical classification of immune cell transcriptomes at population-scale.bioRxiv : the preprint server for biology · 2026Article
- Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.International journal of molecular sciences · 2026Article
- Mass Cytometry Workflow to Achieve High-Dimensional Immunophenotyping in Resource-Limited or Decentralized Environments.Current protocols · 2026Article
- Self-collected finger-prick blood for gene expression profiling: Unveiling early immune responses in mild COVID-19.iScience · 2026Article
- Emerging roles of basophils in the resolution of acute respiratory distress syndrome.The European respiratory journal · 2025Article
- Article
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- Association of LEF1-AS1 with cardiovascular and neurological complications of COVID-19.Journal of molecular and cellular cardiology plus · 2025Article
- Immune Dysregulation in HIV and COVID-19 Co-infection: Therapeutic Implications.Immunity, inflammation and disease · 2025Article
- Antiviral roles of eosinophils in asthma and respiratory viral infection.Frontiers in allergy · 2025Review
- Altered leukocyte pattern and inflammatory markers in unvaccinated long covid patients: a cross-sectional study.Scientific reports · 2024Article
- Immunologic mediators profile in COVID-19 convalescence.Scientific reports · 2024Article
- Bioinformatics and molecular biology tools for diagnosis, prevention, treatment and prognosis of COVID-19.Heliyon · 2024Review
- Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.Cell reports. Medicine · 2024Article
- The role of hematological parameters in asymptomatic and non-severe cases of Omicron variant infection.Virology journal · 2024Article
- Statistical and computational methods for integrating microbiome, host genomics, and metabolomics data.eLife · 2024Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe disease of SARS-CoV-2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5-7 days of stable disease. Efforts to modulate this hyperinflammation and the associated acute respiratory distress syndrome rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Given that every patient is captured at different stages of infection, longitudinal monitoring of the immune response is critical and systems-level analyses are required to capture cellular interactions. Here, we report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFNγ-eosinophil axis activated before lung hyperinflammation and changes in cell-cell co-regulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.